Increased MicroRNA Activity in Human Cancers by Israel, Ariel et al.
Increased MicroRNA Activity in Human Cancers
Ariel Israel
1, Roded Sharan
2, Eytan Ruppin
2,3, Eithan Galun
1*
1Goldyne Savad Gene Therapy Institute, Hadassah Hebrew University Hospital, Jerusalem, Israel, 2School of Computer Science, Tel Aviv University, Tel Aviv, Israel,
3School of Medicine, Tel Aviv University, Tel Aviv, Israel
Abstract
MicroRNAs (miRNAs) are small regulatory RNAs that act by blocking the translation and increasing the degradation of target
transcripts. MiRNAs play a critical role in many biological processes including development and differentiation and many
studies have shown that major changes in miRNA levels occur in cancer. Since miRNAs degrade target messages, we used
this property to develop a novel computational method aimed at determining the actual biological activity of miRNAs using
variations in gene expression. Using the method described here, we quantified miRNA activity in papillary thyroid carcinoma
and breast cancer, and found a strong and distinctive signal of increased global miRNA activity, embedded in the pertaining
gene expression measurements. Interestingly, we found that in these two cancers, miRNA activity is globally increased, and
is associated with a global downregulation of miRNA target genes. This downreguation of miRNA regulated genes is
particularly noticeable for genes carrying multiple target sites for miRNAs. Among the miRNA-repressed genes, we found a
significant enrichment of known tumor suppressors, thereby suggesting that the increased miRNA activity was indeed
tumorigenic.
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Introduction
MicroRNAs are single-stranded non-coding RNA molecules of
about 22 nucleotides that pair with messenger RNAs (mRNAs)
carrying a complementary sequence [1]. MicroRNAs bind to
target mRNAs within the RNA-induced silencing complex (RISC),
which contains a member of the Argonaute protein family. This
binding prevents translation and accelerates the degradation of the
targeted mRNAs [2]. In the last few years, miRNAs have been
shown to play a key role in the regulation of gene expression, and
there is evidence that miRNAs are involved in central biological
processes, including development, organogenesis, tissue differen-
tiation, cell cycle, and metabolism [3–5]. Remarkably, the spatial
and temporal expression of miRNAs is characteristic of tissues and
developmental stages, and several studies have shown a link
between miRNAs expressed in particular tissue types and
regulation of tissue-specific genes [6].
Changes in miRNA expression have been shown to occur in
cancer [7] However, the nature and impact of most of these
changes remain unclear. Notably, conflicting findings exist over
the question of whether miRNA levels are globally decreased or
increased in cancer. Mature miRNAs have been shown in some
studies to be decreased in cancer [8], while other studies have
detected upregulation of miRNAs in many tumors [9]. One
possible explanation for these diverging findings may be
differences between tumor types, tissues analysed, or even
measurement techniques. Another putative explanation is that
the deregulation that miRNAs undergo in cancer is a complex
process. That is, the outcome of miRNA regulation on gene
expression is dependent not only on the levels of the miRNAs, but
also on numerous other factors that mediate the influence of
miRNAs on their target genes, such as components of the RISC
complex. Consequently, the availability of these factors could
markedly modulate the overall influence of miRNAs effect on their
target genes, and, as a result, provide additional feedback on the
levels of miRNAs themselves. Such global variations of miRNA
activity are suggested by studies that have shown that the
Argonaute2 (EIF2C2) gene, which is incorporated in the RISC
complex, is frequently duplicated in tumors [10]. Since this gene is
not directly involved in miRNA biogenesis, one could expect that
when this gene is duplicated, the degradation of miRNA target
genes would increase, with no associated increase in miRNA
levels. For this reason, we attempted to determine the overall effect
of miRNAs on their target genes, their biological activity, and
designed a method for measuring this effect directly from the
pertaining target gene expression levels.
Our method, called MiRABELLE (MicroRNA Activity Based on
Expression Levels), is based on the observation that miRNAs are
known to accelerate the degradation of their target transcripts, and
that this activity leaves a signature on the mRNA levels of their target
genes. A decrease in the expression levels of mRNAs carrying a
binding site for a miRNA species can be detected upon transfection
with the cognate miRNAs [11]. Additionally, several studies have
shown a clear correlation between miRNAs that are highly expressed
in a given tissue and the downregulation of their target transcripts
[6,12,13]. Thus, a shift of expression of the set of genes targeted by a
miRNA in a sample is an indication that the biological activity of a
corresponding miRNA species changes in this sample.
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expression levels reflect the regulatory effect of higher-order
modules, and therefore, one could assess the impact of these
modules, by observing transcriptional changes [14,15]. In
particular, recent reports have shown that variation in the activity
of miRNAs can be detected by comparing the levels of miRNA
target genes across various tissues [16,17]. Our method, though
similar in its concept, diverges from previously published
approaches in that it is designed to capture characteristic features
of miRNA regulation on mRNA transcripts.
It is widely accepted that miRNA binding is determined
primarily by the 39 untranslated region (UTR) of mRNAs. The
presence of a 7-mer complementary to a miRNA seed (nucleotides
2–8) in the 39 UTR of a gene is a key factor of miRNA
recognition; and several algorithms, such as TargetScan [18,19],
have succeeded to identify miRNA-gene associations by carefully
identifying genes with conserved sequences corresponding to miR
recognition patterns. Nevertheless, an established association
between a miRNA and a target gene does not imply that all
transcripts produced from this gene would be subject to miRNA
regulation. About half of human genes can undergo polyadenyl-
ation at multiple sites, or be subject to alternative splicing
influencing their last exons [20,21], and thus produce transcripts
which differ in their 39 UTR sequences. Among mRNAs
transcribed from such loci, only those that carry the miRNA
recognized sequence between the stop codon and the polyA tail
would be affected by miRNA regulation. This property,
remarkably differentiates miRNA effect from transcription regu-
lation occurring at the gene promoter site, and which affects all
isoforms of the gene. We used this property to design a method
that would specifically assess the effect of miRNA regulation.
This approach is made possible by the fact that some
microarray platforms, like Affymetrix, measure transcript abun-
dance using several sequences taken from the 39 end of the gene.
Affymetrix gene expression data is summarized in probe-sets, and
there are several probe-sets available for most genes. Some of these
probe-sets are reliable indicators of miRNA activity, meaning that
they detect sequences that could only appear in the isoforms of a
gene that include a binding site for a given miRNA: all of the
transcripts detected by these probe-sets would be affected by a
change in the activity of a given miRNA. The first step of our
analysis was thus to identify these probe-sets and the miRNAs for
which they detect activity. We did this by mapping the sequence of
the probes, and determining their position in the gene with regard
to the miRNA target sites predicted for the gene.
MiRABELLE uses the expression values measured by these probe-
sets to calculate a biological activity score for each miRNA seed.
Basically, it takes as input a gene expression dataset and compares, in
each sample, the expression levels of probe-sets that are reliable
indicators for activity of a given miRNA seed ‘‘miR-seed’’, with the
expression levels of other probe-sets present on the array, which serve
as reference. The output of MiRABELLE is a ‘‘miR activity matrix’’,
providing the activity scores for each miRNA family (identified by the
seed sequence), and each sample. By convention, positive scores are
given when targets for a miRNA family display downregulation,
indicating that the biological activity of the cognate miRNAs is
increased in the sample, while negative values are obtained for
upregulation of targets, suggesting a decreased activity.
Methods
MiRABELLE tool
MiRABELLE takes as input an expression dataset and produces
a miR-seed activity matrix,givingforeach sampleinthe dataset,the
activity scores computed for each of the miRNA species for which
predictions exist. Positive values are obtained when targets for a
given miR-seed display more downregulation than the reference,
indicating that the activity of this miR-seed is increased in the
sample, while negative values are obtained for upregulation of
targets, suggesting a decreased activity. This tool is written in Perl.
MiR-seeds activity score calculation
MiRABELLE first standardizes the gene expression levels
reported in the input dataset using Z-scores, to correct for the
varying sensitivity of probe-sets, and disparity between average
level of transcripts present in the tissue. Next, it uses the t-statistic
to calculate activity scores, comparing, in each sample, the Z-
scores of probe-sets that are reliable detectors of a given miR-seed,
with the Z-scores of other probe-sets. We used the two-tailed, two-
sample t-statistic, with unequal variance (two sample Welch’s t-
statistic). On a randomly shuffled gene expression dataset, the
variance of this statistic is 1, and its distribution is normal when
based on at least 20 detector probe-sets.
MiRNA targets predictions
In this study, we used TargetScan 4.0 predictions (July 2007) of
miRNA targets [18,19]. TargetScan 4.0 uses both evolutionary
conservation, and specific context determinants to predict miRNA
targets. Targetscan 4.0 predictions are available for about 158
different conserved miRNA seeds, representative of about 450
mature miRNAs in the human. Among these miR-seeds, four were
reliably detected by less than 20 probe-sets in the microarray, and
were hence excluded from the analyses.
Mapping of probe-sets to miR-seeds
In Affymetrix gene expression microarrays, it is common to have
several probe-sets for the same gene, each recognizing a different
sequence. According to the location of the sequences recognized by
probe-sets, it is possible to determine whether a given probe-set
detects only isoforms that carry a miR-seed target site, or also
isoforms that may be exempt from the miR-seed target site. Probe-
sets detecting exclusively transcripts carrying a miR-seed target are
more strongly affected by miRNA regulation than probe-sets that
detect a region of the gene shared by transcripts that do not carry the
miR target sequence. Thus, a prior step to our analysis was to assign
to each probe-set available on the microarray a list of miR-seeds that
will affect all the isoforms detected by the probe-set. We used the
following rule for assigning probe-sets to miR-seeds: when the
sequence corresponding to a given miR-seed is directly recognized by
a probe-set or is located upstream to the sequences detected by the
probe-set in the gene and on the same exon, we consider this probe-
set to be a reliable indicator of activity for this miR-seed. However, if
the sequence corresponding to this miR-seed is located downstream
to the sequences recognized by the probe-set, the probe-set might
detect short mRNAs that do not contain a miRNA target sites, and
we do not assign it to the miR-seed. We performed this mapping
using the UCSC genome browser database [22], human build 17
(http://genome.ucsc.edu). We downloaded the TargetScan predic-
tions from the website (http://www.targetscan.org) and mapped
them to the UCSC genome; we used the ‘‘knownGene’’ table for
mapping chromosomal locations to genes; we used the ‘‘affyU133-
Plus2’’ and ‘‘affyU133’’ tables for finding the location of sequences
recognized by probe-sets in the genes (Text S1).
Datasets analyzed
Pappilary thyroid carcinoma and breast cancer datasets were
retrieved from the GEO database [23], accession GSE3467,
MicroRNA Activity in Cancer
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882. We used the normalized expression values from the database.
When raw data was available, we downloaded it, and renorma-
lized it using GCRMA, RMA and MAS 5.0 packages on
Bioconductor [25]. MiRABELLE predictions and enrichment of
downregulated targets were not significantly affected by the
normalization algorithm used. Validation experiments of trans-
fection with microRNAs and antagomirs were retrieved from the
GEO database, accession GDS1858, GDS2657, and GSE3425.
TF enrichment analysis
Binding sites (BS) for TF were determined by scanning the
promoters of all probe-sets present in the affymetrix microarray for
matches with Transfac matrices, as described in [26]. In each
promoter, the 500 base pairs (bp) immediately before the
transcription start sites were scanned, in accordance with the fact
that most active TFBS appear close to the transcription start site
[27]. The hypergeometric distribution was used to assess
enrichment between the background set of probe-sets and a
sample set.
GO Annotations
We used the GO biological process annotations for the
U133Plus2 array from Affymetrix website (http://www.affyme-
trix.com).
Statistics
We used the two-tailed, two-sample t-test with equal variance in
order to identify the miR-seeds showing the most significant
deviations in tumors vs. normal tissues, and ranked these MiRs
according to this test. This test was performed in Excel. We
performed one sample Kolmogorov-Smirnov (KS) tests to assess
the normality of the distribution of miR activity scores computed
by MiRABELLE on the dataset, and two-sample KS tests for
comparing the distributions of miR activity scores computed from
the original and a randomly shuffled dataset. The KS tests and the
associated histograms were performed in Matlab 7 (Mathworks).
The enrichment tests were performed using the hypergeometric
cumulative distribution function in Matlab.
Enrichment of downregulated genes with increasing
number of miR target sites (Table 1)
For the given set of miR-seeds, we performed enrichment tests
iteratively for each i between 0 and the maximal number of target
sites, as follows. The total population size (N) was the number of
informative probe-sets having at least i target sites for the
considered set of miR-seeds, the number of probe-sets reporting
downregulation were counted as successes (m). We tested for
enrichment of downregulation in the sample of probe-sets
detecting at least i+1 target sites for these miR-seeds.
Enrichment of GO annotations (Table S6)
We used the hyper-geometric distribution to identify the most
significantly enriched annotations in the sample of 9542 probe-sets
associated with the 77 miR-seeds, with regard to the population of
all probe-sets on the array (A). 5069 of these miR targets were
effectively downregulated in tumors. In the second analysis, we
identified the most significantly enriched annotations in the sample
of 5069 downregulated probe-sets, with regard to the population
of the 9542 predicted targets (B).
Table 1. Gene expression trends obtained for probe-sets that were mapped to the 77 miR-seeds that were found by t-test to
display the most significant upregulation in breast cancer (FWER p,0.05).
minimal number of
target sites in transcripts Up- Down-
percentage of
downregulated probe-sets
P-value for enrichment
(hypergeometric distribution)
regulated probe-sets
0 23660 16879 41.6%
1 4473 5069 53.1% 5.94?10
2148
2 2999 3575 54.4% 1.36?10
24
3 2164 2715 55.6% 2.66?10
24
4–5 1576 2104 57.2% 9.87?10
25
6–7 882 1316 59.9% 3.27?10
25
8–9 547 821 60.0% 4.48?10
21
10–11 303 547 64.4% 1.81?10
25
12–13 191 341 64.1% 6.08?10
21
14–15 117 250 68.1% 2.81?10
23
16–18 69 159 69.7% 2.30?10
21
19–21 42 92 68.7% 7.15?10
21
22–24 24 59 71.1% 2.79?10
21
25–26 12 32 72.7% 4.56?10
21
27–30 6 21 77.8% 2.72?10
21
31–33 2 9 81.8% 5.28?10
21
.=34 0 9 100.0% 1.82?10
21
The table gives the expression trends observed from probe-sets, according to the number of target sites predicted in the transcripts they detect. We observe that the
proportion of probe-sets detecting downregulation in tumors gradually increases with the number of target sites for these miRs, and this increase is associated with
significant hypergeometric p-values.
doi:10.1371/journal.pone.0006045.t001
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Validation of the MiRABELLE Method
We first validated the MiRABELLE method in tissues where the
abundance of a particular miRNA had been experimentally
increased. Lim et al. [11] transfected HeLa cells with miR-124,
miR-1, and miR-373, and measured gene expression after 12 and
24 hours. Wang et al. [28] transfected HepG2 cells with miR-124
and measured gene expression at various time intervals. We
subjected the gene expression data to MiRABELLE analysis, which
computed themiR-seedactivityforeachsample.Inthesamplesthat
were transfected with microRNAs, our tool correctly identified very
significant increases in microRNA activity, specifically for the miR-
seeds miR-124, miR-1, and miR-373, in the corresponding
experiments (Text S1). In order to ensure that MiRABELLE is
suitable for detection of changes of miRNA activity occurring in vivo,
we analyzed the gene expression data generated in the experiment
of Krutzfeldt et al., where miR-122 was silenced by systemic
injection of an antagomir [29]. We found that our tool correctly
identified the significant decrease of activity for miR-122 occuring
after treatment with the antagomir (Text S1).
Inferring MicroRNA activity in Human Papillary Thyroid
Carcinoma
Papillary Thyroid Carcinoma (PTC) is a malignancy that
accounts for ,80% of human thyroid cancers. Two independent
studies have reported specific alterations of miRNA levels in PTC.
It was therefore interesting to quantify the biological activity of
miRNAs in PTC using the MiRABELLE tool and compare these
with the changes in miRNA expression levels reported in these two
studies.
He et al. [30] measured miRNA levels in tissue samples from 15
PTC patients using miRNA microarrays. Concomitantly, they also
used Affymetrix microarrays to determine gene expression in nine
tumors (T-PTC) and nine paired surrounding tissues (N-PTC). We
analyzed the gene expression data using MiRABELLE to infer a
miR-seed activity matrix (Table S1). As evident from this table,
miR-seed activity scores were substantially higher in tumors than
in normal tissues, suggesting that PTC tumors are characterized
by an intensification of miRNA activity. Indeed, the median
miRNA activity score in tumors is higher than the median activity
score in normal samples for 97% of the miR-seeds. To determine
the miR-seeds for which the increase of activity is the most
pronounced in tumors, we used the two-sample t-test to compare
the activity scores obtained from normal and tumor samples
(Table S2). He et al., reported that miR-146, miR-221, miR-222
and miR-21, displayed the most dramatic overexpression in
tumors with levels 19- to 4-fold higher in tumors than in adjacent
tissue. The t-test applied to our activity scores (using only the
subset of seeds that were used by He et al., in their microRNA
array) has successfully identified the 3 miR-seeds belonging to
these 4 microRNAs among the six most significant p-values (out of
65 different seeds). Thus, in the PTC case, the top miR-seeds
identified by their biological activity coincide with the top
overexpressed miRNAs.
The match between our predictions and the biological
measurements is not incidental and as we show below, results
from a very strong signal present in gene expression. The activity
scores computed by the MiRABELLE tool are based on t-statistics,
and in the absence of a common regulation of these genes, these
statistics follow a normal distribution. Figure 1A displays the
distribution of the miR-seed activity scores in normal and tumor
tissues. It can be seen that activity scores are significantly higher in
tumors than in normal tissues (p,10
2125 by a Kolmogorov-
Smirnov (KS) test). As a control, we computed hypothetical
activity scores on the same dataset after random shuffling of the
probe-sets (Fig. 1B). In the latter case, the KS test does not detect a
significant difference between the distribution of activity scores in
tumor and normal tissues, as one would expect.
Inferring MicroRNA activity in breast cancer
Having found that microRNA activity is globally increased in
papillary thyroid carcinoma, we proceeded to investigate miRNA
activity in breast cancer, which is the second most common type of
cancer, and a subject of extensive studies on gene expression, with
some very valuable datasets available in public repositories.
Richardson et al., published a gene expression study on breast
cancer [31], which is based on a dataset that included seven
normal tissue samples and 40 breast tumors, among which 18 were
basal-like cancers (BLC), a poorly differentiated and highly
aggressive form of cancers. The activity matrix inferred for this
dataset appears in Table S3. As demonstrated in Figure 1C, the
level of miRNA biological activity in tumor samples is here also
significantly higher than in normal samples; the KS test shows that
activity scores in tumor and normal samples have a distinct
distribution (p,10
2298). Comparing the median activity scores in
cancer and normal tissue samples, all but four miR-seeds appear to
have higher activity in cancer than in normal tissue. Even after
choosing a restrictive cut-off of p,3?10
24 (corresponding to a 0.05
significance level after a Bonferroni correction for multiple testing),
we find that 77 (out of the 150) miR-seeds have a significant
increased activity in tumors (Table S4). Altogether, the micro-
RNAs corresponding to these 77 miR-seeds are predicted by
TargetScan to regulate about 6,000 genes. The increased miRNA
activity observed is indeed reflected in a marked decrease in the
expression of these target genes. Out of the 9,542 probe-sets
associated with transcripts regulated by one of these 77 miR-seeds,
5,069 (53.1%) have lower average expression in tumors (i.e., the
corresponding target genes are downregulated) than in normal
tissue, compared with 41.6% of all the 40,539 probe-sets in the
array (p,10
2147 by a hypergeometric test, Figure 1).
To provide additional support for our conclusion that micro-
RNAs are the main cause of the massive downregulation of these
genes, we examined the extent of gene target downregulation as a
function of the number of the associated binding sites for the miR-
seeds. This investigation has been motivated by previous
observations suggesting that the mRNA degradation following
binding of miRNA is more efficient for transcripts carrying
multiple target sites for miRNAs [32–34]. Table 1 summarizes the
expression trends observed for probe-sets that are mapped to the
77 miR-seeds displaying the most significant increase of activity in
tumors. As mentioned above, 9,542 probe-sets detect transcripts
that have at least one binding site for MiR-seeds, 53.1% of them
displaying downregulation in tumors. When one considers the
6,574 probe-sets detecting transcripts carrying at least 2 target
sites, the percentage improves to 54.4% (p,1.3?10
24 by a
hypergeometric test), and it continues to increase for probe-sets
detecting transcripts carrying more sites for miRNA binding,
reaching about 70% for the 228 probe-sets detecting transcripts
with more than 15 target sites. It is remarkable that even though
MIRABELLE algorithm did not use the number of miRNA
binding sites in its calculations–activity scores were computed from
probe-sets identified as indicators of a miR-seed, regardless of the
number of binding sites they may carry–the miRNAs that it
identified as undergoing a significant change activity, displayed a
clear dose-response effect. Hence, the gradual increase in the
proportion of downregulated genes with the number of target sites
MicroRNA Activity in Cancer
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of target genes is indeed due to increased miRNA activity.
Since many genes are regulated by several miRNA species, we
wished to ensure that the detected global downregulation of
miRNA target genes was not due to the increase in just a few
specific species of miRNAs (which share target genes with the
other miRNA species) out of this set of 77 active miR-seeds. To
this end, we performed the hypergeometric enrichment test
described earlier (i.e,. testing for enrichment of down-regulated
genes among probe-sets that detect targets of at least one miR-seed
in the set examined) in an iterative manner. In the first iteration,
we examined the hypergeometric enrichment obtained when
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Figure 1. Distribution of the MiR activity scores calculated for tumor samples (red) and normal samples (cyan). (A) Histogram
displaying the distribution of miR-seed activity scores computed for tumor (red) and normal samples (cyan) in the papillary thyroid carcinoma
dataset. Activity of miRNAs is globally higher in tumor tissues relative to normal tissues. The KS test rejects the hypothesis of equality of the
distributions of activity scores in tumor and in normal tissues, with a p-value P<10
2126. Normality of the activity scores is rejected with P,10
2300. (B)
To show that the deviation between scores computed for normal and tumor tissues is not due to our method of calculating the activity scores, we
computed these scores from a random permutation of the probe-sets from the PTC dataset. For both normal and tumor tissues, the activity scores
follow approximately a normal distribution, as expected for a t-statistic. There is no observable deviation between tumor and normal tissues, and the
KS test does not reject equality of the two distributions. (C) Histogram displaying the distribution of miR-seed activity scores computed for tumor
(red) and normal samples (cyan) in breast cancer dataset. MiRNA activity is significantly higher in tumor tissues relative to normal tissues. The KS test
rejects the hypothesis of equality of the distributions of activity scores in tumor and in normal tissues, with a p-value P,10
2298. (D) Histogram
displaying the distribution of miR-seed activity scores for a random permutation of the probe-sets from the breast dataset.
doi:10.1371/journal.pone.0006045.g001
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miR-seed. In the second iteration, we examined the hypergeo-
metric enrichment obtained when considering the expression
patterns of the targets of the first and second miR-seeds, and so on.
Remarkably, the best score was obtained when considering the
targets of the first 74 miR-seeds, confirming that, indeed, almost
all of the original 77 biologically-active miRNA species contribute
to the observed expression downregulation. To ensure that these
results were not due to specific features of the analyzed data, we
investigated other breast cancer datasets, such as E-MEXP-882
[35], and processed them with different normalization schemes
(GC-RMA, MAS5.0). Using the hypergeometric test, we found a
similarly significant downregulation of miRNA target genes (81
biologically-active miR-seeds, p,10
2134 hypergeometric enrich-
ment test), furthering strengthening the hypothesis that the global
downregulation of miRNA targeted genes observed in breast
cancer is not specific to a particular study.
A potential cause for the observed downregulation of micro-
RNA target genes could be the action of transcription factors (TFs)
that co-regulate those genes [36]. Searching for known TF binding
sites in the promoter regions of target transcripts of each of the 77
miR-seeds, we found a significant enrichment (p,0.05) for 82 TFs
(Methods). Binding sites for these TFs were found in 30% of the
probe-sets present in the array. After excluding all transcripts with
putative binding sites for those TFs, we still observed a very
significant p-value for enrichment of downregulated genes among
miRNA targets (p,10
296).
Next, we set to list the genes that have predicted target sites for
the 77 miR-seeds and are therefore expected to be affected by the
increased miRNA activity (Table S5). We functionally character-
ized them using gene ontology (GO) annotation, and looked for
statistical enrichment of specific annotations (Table S6). This
analysis shows that several biological processes were overrepre-
sented among gene targets of these miRNAs: regulation of
transcription, development and differentiation, ubiquitin cycle,
signal transduction, transport, and tumor suppression (synonym
category: regulation of progression through cell cycle) (FDR
p,10
29). As we saw earlier, most of these genes displayed
decreased expression values in tumors, but not all. We looked for
functional annotations that could characterize the probe-sets that
were downregulated in tumors, compared to the other predicted
targets that were not effectively downregulated. We found that
cell-cycle arrest was the most significantly enriched annotation
(FDR p,2?10
22), suggesting that miRNA-regulated genes that
cause cell-cycle arrest are indeed downregulated in tumors.
Since the efficiency of gene silencing by microRNAs improves
with the number of target sites, we looked for genes carrying the
highest number of target sites for our 77 miR-seeds. This
corresponds to the top of Table S5. In accordance with the top
identified GO annotations, we find genes regulating gene
transcription: CPEB4 (cytoplasmic polyadenylation element bind-
ing 4), which encodes a protein believed to control polyadenyl-
ation-induced translation in early development, has the highest
number of target sites (38), and is downregulated. Two other
members of the CPEB family, CPEB2 and CPEB3, also appear
high in the list with 26 and 25 target sites, respectively, and are
also downregulated; DDX3X (DEAD box polypeptide 3, X-linked),
a RNA helicase, has 33 target sites, and its associated probe-sets
also report downregulation (p=0.002, 0.00001); PURB (Purine-
rich element binding protein B), a single-stranded DNA binding
protein that is implicated in the control of both DNA replication
and transcription has 30 target sites (deletion of this gene has been
associated with myelodysplastic syndrome and acute myelogenous
leukemia) and is downregulated. MECP2 (methyl CpG binding
protein 2), which participates in the repression of methylated
promoters, carries 29 sites, and appears to be efficiently silenced (t-
test p<0.001 for 2 probe-sets detecting transcripts with target
sites); likewise ZBTB4, a CpG binding protein that participates in
the repression of transcription from methylated promoters carries
22 sites and its transcript levels appear to be significantly reduced
(p,10
27).
We also find important tumor suppressors: FOXP1 (Forkhead
box P1), a transcription factor that is believed to act as a tumor
suppressor as it is lost in several tumor types, carries 15 predicted
target sites from the most upregulated miR-seeds, and a significant
downregulation is detected. Also, KLF4 (Kruppel-like factor) that
controls the G1/S cell cycle checkpoint upon DNA damage has 14
predicted target sites for the most upregulated miR-seeds; (t-test
showing that its expression levels are very significantly reduced in
cancer (p,0.000001 for the two probe-sets available for this
gene)). ESR1 (estrogen receptor 1), a gene frequently silenced in
breast cancer, carries 12 predicted miRNA targets, and is
downregulated. Interestingly, PDCD4 (Programmed Cell Death
4), a tumor suppressor whose inhibition in breast cancer has been
linked to an increase in miR-21 [37], has 7 target sites for this
group of miRNAs (including one for miR-21), and here is also
significantly downregulated.
Lu et al. [8] have shown that microRNA levels measured by
bead-flow permit the classification of human cancers by non-
supervised methods such as hierarchical clustering. To ascertain
that the miRNA activity scores computed by MIRABELLE do
also provide this level of information, we subjected the miR-seed
activity matrix produced for the breast cancer datasetto hierar-
chical clustering [38]. Interestingly, hierarchical clustering based
on activity scores allowed to distinguish between tumor and non-
tumor samples (Fig. 2). Moreover, the clustering procedure
appears to distinguish between subtypes of tumors, with most
BLC samples grouped together.
Discussion
We have described here a method that allows inferring of
miRNA activity from gene expression data. During the course of
this study, other reports were published presenting analogous
approaches [16,17], which also concluded that miRNA regulation
information can be extracted from gene expression data. The
method we present here, although similar in its principle with the
methods described in these reports, is the first to incorporate input
from the location of the probes within the gene to detect variations
that are specific to changes in miR activity. By applying this
method to two types of human cancer, we found a strong signal of
increased miRNA activity in tumors. This increase appears to
have a very significant impact on gene expression, and we observe
a substantial number of miRNA target genes downregulated in
tumors, with the downregulation being stronger for genes carrying
multiple sites for miRNAs. Among these genes, we identified a
significant enrichment of tumor suppressor genes, suggesting a
mechanism by which the increase in miRNA activity could be
advantageous to tumors. In addition to their destabilizing effect on
mRNA transcripts, microRNAs have been shown to repress
protein translation, and therefore, one could expect that at the
protein level, these miRNAs repressed genes are even more
strongly silenced than what their probe-sets suggest.
Our method uses the changes in mRNA levels detected by
indicator probe-sets to measure changes in miRNA activity across
samples. It is remarkable that the moderate fluctuations exerted by
miRNAs at the mRNA level, could give such a strong signal of
miRNA activity when collected from these probe-sets, and this
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represses hundreds of genes at the mRNA level [11,39,40]. In
addition, the statistical signal of miRNA activity in gene expression
data has also been observed in two recent reports [16,17].
Our activity scores are based on variations in levels of mRNA
transcripts, and the specific effect of microRNAs on protein
translation is not assessed by these scores. Nonetheless, there is
increasing evidence that the translational effect of microRNAs is
accompanied by changes in mRNA level, and that mRNA
destabilization is the dominant component of repression. Baek et
al. [39], have shown that genes undergoing microRNA repression
by more than a third also display detectable mRNA destabiliza-
tion, and that highly repressed targets were silenced primarily at
the mRNA level. Additionally, Selbach et al. [40] showed that
most microRNA targets are repressed both at the mRNA and the
translational levels. MicroRNA species typically repress hundreds
of targets, and most of them are repressed at least at the mRNA
level. Therefore, it is reasonable to think that microRNAs that
decrease or increase significantly their activity would be noticed by
their effect on mRNA levels.
The increase in activity of miRNAs that we identified in the two
types of cancer studied could be due either to increased biogenesis
of miRNAs, or to improved efficiency of the mediators of miRNA
effect on target genes. In the first case, the increase in miRNA
activity would have to be accompanied by an increase in the levels
of miRNAs, while in the latter, mature miRNA transcripts levels
Figure 2. Hierarchical clustering of breast samples by MiR-seed activity scores. Clustering was done by complete linkage on cluster 3.0
according to the correlation (centered) similarity metric, after selecting miR-seeds for which the SD is at least 4. It can be observed that normal
samples are clustered together. Most of the BLC tumor samples are also grouped together. Prior to clustering, samples were randomly shuffled. Color
code: red means increased activity of miR-seeds; green decreased (Spearman rank correlation, complete linkage).
doi:10.1371/journal.pone.0006045.g002
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an increase in the level of few miRNAs species has been reported
[30,41,42], but not a global increase in the levels of many miRNA
species. Such a global increase could suggest an alteration in the
post-biogenesis regulation of the miRNA effects. This may possibly
occur at the level of the Argonaute proteins, which form the core
components of the RISC effector complex RISC mediating
miRNA function [1]. In support of this hypothesis, a genome-wide
search for copy number alterations in cancer has shown frequent
duplication of the Argonaute2 (EIF2C2) gene, as well as DICER1
in tumors [10].
Interestingly, Kumar et al., have found that tumorigenesis is
accelerated after DICER conditional deletion in the K-ras model
of lung cancer, and that RNA interference against DICER
increases cell-growth in several tumor cell lines [43]. This suggests
that DICER repression, and hence reduction of miRNA activity,
enhances tumorigenesis, and could appear to conflict with our
findings that breast cancer and PTC are accompanied by an
increase in miRNA activity. In accordance with Kumar et al., who
stated that other studies showed that overexpression of miRNAs
accelerates tumorigenesis, we do not think that there is a
contradiction here, and the effect of changes in miRNA activity
are likely to vary with cancer types and stages of tumorigenesis.
Further biological studies would be needed to confirm the
increase of miRNA activity identified here bioinformatically in two
types of cancer and identify its mechanism. If the downregulation
is confirmed, this would suggest that the increase in miRNA
activity occurring in certain types of cancer as reported here may
play a key role in the pathogenesis of these types of cancers, and
could offer an attractive diagnostic and therapeutic avenue.
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